7,017 reports of this reaction
7.8% of all DAPAGLIFLOZIN reports
#1 most reported adverse reaction
DEATH is the #1 most commonly reported adverse reaction for DAPAGLIFLOZIN, manufactured by AstraZeneca Pharmaceuticals LP. There are 7,017 FDA adverse event reports linking DAPAGLIFLOZIN to DEATH. This represents approximately 7.8% of all 89,435 adverse event reports for this drug.
Patients taking DAPAGLIFLOZIN who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEATH is moderately reported among DAPAGLIFLOZIN users, representing a notable but not dominant share of adverse events.
In addition to death, the following adverse reactions have been reported for DAPAGLIFLOZIN:
The following drugs have also been linked to death in FDA adverse event reports:
DEATH has been reported as an adverse event in 7,017 FDA reports for DAPAGLIFLOZIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEATH accounts for approximately 7.8% of all adverse event reports for DAPAGLIFLOZIN, making it one of the most commonly reported side effect.
If you experience death while taking DAPAGLIFLOZIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.